Armata Pharmctcl Financials
This page shows Armata Pharmctcl (ARMP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 13 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Armata Pharmctcl passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.
For every $1 of reported earnings, Armata Pharmctcl generates $0.15 in operating cash flow (-$25.8M OCF vs -$173.8M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Armata Pharmctcl's EBITDA was -$35.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 14.6% from the prior year.
Armata Pharmctcl reported -$173.8M in net income in fiscal year 2025. This represents a decrease of 818.8% from the prior year.
Armata Pharmctcl earned $-4.80 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 439.3% from the prior year.
Cash & Balance Sheet
Armata Pharmctcl generated -$26.3M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 33.3% from the prior year.
Armata Pharmctcl held $8.7M in cash against $0 in long-term debt as of fiscal year 2025.
Armata Pharmctcl had 37M shares outstanding in fiscal year 2025. This represents an increase of 1.2% from the prior year.
Margins & Returns
Capital Allocation
Armata Pharmctcl invested $23.7M in research and development in fiscal year 2025. This represents a decrease of 31.1% from the prior year.
Armata Pharmctcl invested $542K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 71.2% from the prior year.
ARMP Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $5.8M-8.9% | $6.4M+17.8% | $5.4M | N/A | $9.5M+11.9% | $8.5M+5.7% | $8.0M | N/A |
| SG&A Expenses | $3.1M+18.8% | $2.6M-19.5% | $3.3M | N/A | $3.2M-5.7% | $3.4M+8.2% | $3.2M | N/A |
| Operating Income | -$7.8M-13.6% | -$6.8M+16.4% | -$8.2M | N/A | -$9.8M+18.1% | -$11.9M-16.5% | -$10.2M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | $2.7M+49.3% | $1.8M | N/A |
| Income Tax | $0 | N/A | $0 | N/A | $0 | $0 | $0 | N/A |
| Net Income | -$26.7M-63.7% | -$16.3M-149.5% | -$6.5M | N/A | -$5.5M-161.0% | $9.0M+135.9% | -$25.0M | N/A |
| EPS (Diluted) | $-0.74-64.4% | $-0.45-125.0% | $-0.20 | N/A | $-0.15+40.0% | $-0.25+63.8% | $-0.69 | N/A |
ARMP Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $89.5M+10.8% | $80.8M-7.4% | $87.3M+0.9% | $86.4M-12.0% | $98.2M-9.3% | $108.3M-10.0% | $120.4M+22.4% | $98.4M |
| Current Assets | $16.9M+125.1% | $7.5M-42.9% | $13.2M+16.4% | $11.3M-49.5% | $22.4M-27.6% | $30.9M-25.9% | $41.7M+117.8% | $19.2M |
| Cash & Equivalents | $14.8M+240.9% | $4.3M-63.0% | $11.7M+25.8% | $9.3M-45.8% | $17.1M-35.1% | $26.4M-30.3% | $37.9M+180.0% | $13.5M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M0.0% | $3.5M |
| Total Liabilities | $185.1M+23.2% | $150.3M+6.6% | $141.0M+4.9% | $134.5M-9.9% | $149.2M-3.4% | $154.4M-12.7% | $176.9M+35.6% | $130.4M |
| Current Liabilities | $139.9M+16.5% | $120.1M+8.6% | $110.5M+129.1% | $48.2M-59.2% | $118.2M-4.0% | $123.2M+11.9% | $110.0M+568.5% | $16.5M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$95.6M-37.5% | -$69.5M-29.2% | -$53.8M-12.0% | -$48.0M+5.8% | -$51.0M-10.6% | -$46.1M+18.4% | -$56.5M-76.2% | -$32.1M |
| Retained Earnings | -$377.2M-7.6% | -$350.6M-4.9% | -$334.3M-2.0% | -$327.7M+0.8% | -$330.3M-1.7% | -$324.9M+2.7% | -$333.8M-8.1% | -$308.8M |
ARMP Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.3M+40.4% | -$7.2M+4.9% | -$7.6M+4.4% | -$7.9M+10.6% | -$8.9M+12.9% | -$10.2M+3.8% | -$10.6M-30.6% | -$8.1M |
| Capital Expenditures | $242K+62.4% | $149K+50.5% | $99K+228.6% | -$77K-122.6% | $340K-75.1% | $1.4M+446.4% | $250K-89.6% | $2.4M |
| Free Cash Flow | -$4.5M+38.3% | -$7.4M+4.2% | -$7.7M+4.1% | -$8.0M+13.0% | -$9.2M+20.3% | -$11.5M-6.5% | -$10.8M-3.1% | -$10.5M |
| Investing Cash Flow | -$242K-62.4% | -$149K-50.5% | -$99K-228.6% | $77K+122.6% | -$340K+75.1% | -$1.4M-446.4% | -$250K+89.5% | -$2.4M |
| Financing Cash Flow | $15.0M | $0-100.0% | $10.0M | $0+100.0% | -$61K-169.3% | $88K-99.7% | $34.9M+81334.9% | -$43K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ARMP Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -29.8%-9.6pp | -20.2%-12.7pp | -7.5% | N/A | -5.6%-13.9pp | 8.3%+29.1pp | -20.8% | N/A |
| Current Ratio | 0.12+0.1 | 0.06-0.1 | 0.12-0.1 | 0.23+0.0 | 0.19-0.1 | 0.25-0.1 | 0.38-0.8 | 1.16 |
| Debt-to-Equity | -1.94+0.2 | -2.16+0.5 | -2.62+0.2 | -2.80+0.1 | -2.93+0.4 | -3.35-0.2 | -3.13+0.9 | -4.07 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$218.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
Is Armata Pharmctcl profitable?
No, Armata Pharmctcl (ARMP) reported a net income of -$173.8M in fiscal year 2025.
What is Armata Pharmctcl's EBITDA?
Armata Pharmctcl (ARMP) had EBITDA of -$35.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Armata Pharmctcl's free cash flow?
Armata Pharmctcl (ARMP) generated -$26.3M in free cash flow during fiscal year 2025. This represents a 33.3% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Armata Pharmctcl's operating cash flow?
Armata Pharmctcl (ARMP) generated -$25.8M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Armata Pharmctcl's total assets?
Armata Pharmctcl (ARMP) had $76.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Armata Pharmctcl's capital expenditures?
Armata Pharmctcl (ARMP) invested $542K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Armata Pharmctcl spend on research and development?
Armata Pharmctcl (ARMP) invested $23.7M in research and development during fiscal year 2025.
What is Armata Pharmctcl's current ratio?
Armata Pharmctcl (ARMP) had a current ratio of 1.19 as of fiscal year 2025, which is considered adequate.
What is Armata Pharmctcl's debt-to-equity ratio?
Armata Pharmctcl (ARMP) had a debt-to-equity ratio of -1.35 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Armata Pharmctcl's return on assets (ROA)?
Armata Pharmctcl (ARMP) had a return on assets of -226.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Armata Pharmctcl's cash runway?
Based on fiscal year 2025 data, Armata Pharmctcl (ARMP) had $8.7M in cash against an annual operating cash burn of $25.8M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Armata Pharmctcl's debt-to-equity ratio negative or unusual?
Armata Pharmctcl (ARMP) has negative shareholder equity of -$218.6M as of fiscal year 2025, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Armata Pharmctcl's Piotroski F-Score?
Armata Pharmctcl (ARMP) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Armata Pharmctcl's earnings high quality?
Armata Pharmctcl (ARMP) has an earnings quality ratio of 0.15x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.